Business context and reporting period
Filing identity mismatch: The supplied filing is Rexahn Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2012, not a filing by Opus Genetics, Inc. The summary below reflects the filing itself.
Rexahn described itself as a development-stage biopharmaceutical company developing treatments for cancer and other conditions. It had no commercial product sales. Financial results cover the three and six months ended June 30, 2012, compared with the same 2011 periods.
Financial results and liquidity
| Metric | Three months ended June 30, 2012 | Six months ended June 30, 2012 | Comparable 2011 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $1.018 million | $2.061 million | $5.417 million; $8.135 million |
| General and administrative expense | $743,000 | $1.471 million | $928,000; $2.037 million |
| Total expenses | $1.849 million | $3.733 million | $6.459 million; $10.372 million |
| Net loss | $1.042 million | $3.182 million | $5.829 million; $10.265 million |
| Basic and diluted loss per share | $0.01 | $0.03 | $0.06; $0.11 |
| Operating cash used | Not reported separately | $3.896 million | $7.491 million |
Profit margins are not meaningful because the company reported no revenue and incurred operating losses. The company recorded a non-cash gain from remeasuring warrant liabilities of $802,000 for the quarter and $540,000 for the six-month period; this reduced reported losses but did not represent operating revenue.
- At June 30, cash and cash equivalents were $8.483 million, restricted cash equivalents were $764,000, and marketable securities were $100,000. Management reported these combined resources as $9.347 million.
- Total assets were $9.759 million; total liabilities were $2.093 million. Stockholders’ equity was $7.666 million. The company reported no debt instruments on its balance sheet.
- Cash and cash equivalents declined by $1.379 million from December 31, 2011. There were no financing cash flows in the first half of 2012.
- Accumulated deficit was $60.267 million. Accounts payable and accrued expenses were $891,000, and warrant liabilities were $328,000.
Material changes versus the prior comparable period
- First-half net loss narrowed to $3.182 million from $10.265 million; second-quarter net loss narrowed to $1.042 million from $5.829 million.
- R&D expense fell substantially, primarily because the Serdaxin Phase IIb trial was underway in 2011 but not in 2012. G&A expense also declined, in part due to lower stock-option compensation and professional and legal fees.
- Cash used in operations declined to $3.896 million from $7.491 million in the first half. The 2011 period included significant equity financing; no financing proceeds were recorded in the first half of 2012.
- Interest income fell to $10,543 for the first half from $81,322, reflecting lower interest-bearing investments and lower rates.
Outlook, management commentary, risks and unusual items
- Management expected available cash, restricted cash and securities to cover minimum planned operating needs through June 30, 2013, while stating that additional financing would be needed to execute the broader development plan. It cautioned that financing might not be available on acceptable terms.
- For the next 12 months, management outlined approximately $800,000 for Archexin clinical development, $50,000 to close out the Serdaxin trial, $3.2 million for RX-3117 and the preclinical pipeline, $4.0 million for general corporate expenses, and $220,000 for facilities rent.
- Archexin’s pancreatic-cancer Phase IIa trial had completed enrollment; results were anticipated in the third quarter of 2012. A Phase II ovarian-cancer trial was planned for the second half of 2012, with estimated costs of approximately $900,000.
- Serdaxin did not demonstrate efficacy versus placebo in its Phase IIb depression study; the company had not allocated resources to further develop it for major depressive disorder. Management was evaluating how to proceed with Zoraxel, which shares Serdaxin’s active ingredient.
- RX-3117 entered an exploratory Phase I study in early 2012. The filing reports results announced August 6, 2012—after quarter-end—including oral bioavailability and no reported adverse events. Rexahn also submitted an IND for RX-5902 in July 2012 and said it might enter Phase I trials in the second half of 2012.
- Research and development contracts had an estimated remaining cost of approximately $3.138 million ($19.956 million total contract value less $16.818 million paid); agreements could generally be terminated with notice. Development costs and timelines remained uncertain, and clinical trials depended on third parties and regulatory approvals.
- Other risks included the need for additional capital, clinical-trial and regulatory uncertainty, product acceptance, third-party availability and intellectual-property protection. The company reported no material change to previously disclosed risk factors, no legal proceedings, and no off-balance-sheet arrangements.
- Warrant liabilities were valued using a model with significant unobservable assumptions; the resulting gains or losses can be volatile and sensitive to the company’s share price and volatility assumptions. Management reported effective disclosure controls as of period-end.
Most important facts for investors to verify
- Confirm the issuer: this source is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Review the company’s cash runway and financing needs, including the restricted portion of cash and whether planned spending can be funded without new capital.
- Check subsequent clinical updates and timelines for Archexin, RX-3117, RX-5902, Serdaxin and Zoraxel, distinguishing post-quarter developments from results available at June 30.
- Assess the assumptions behind warrant-liability fair values and the extent to which non-cash gains affected reported net loss.
- Verify remaining research-contract commitments, clinical-development estimates, and any changes in financing, trial plans or regulatory status after the filing date.